Blueprint’s Selective CDK2 Inhibitor for the Treatment of CDK4/6-Inhibitor-Resistant Breast Cancer and CCNE1-Amplified Solid Tumors

BLU-222

oral selective CDK2 inhibitor Ph. I/II for advanced solid tumors SBDD from initial selectivity-driven hit finding screen ACS Spring 2024 Meeting First Time Disclosure Blueprint Medicines, Cambridge, MA

Author:

Kerry Betz

Reviewer:

Lew Pennington

Editor:

Rory McAtee

Blueprint’s Selective CDK2 Inhibitor for the Treatment of CDK4/6-Inhibitor-Resistant Breast Cancer and CCNE1-Amplified Solid Tumors

BLU-222

Other molecules you may be interested in